Shikonin dampens bone cancer pain behaviors in a rat model by acting on spinal IGF2-p38 signaling
Bone cancer pain remains one of the most difficult pain syndromes to control, in part because tumor growth in bone does more than trigger nociception. It drives persistent inflammation, disrupts skeletal structure, and recruits spinal mechanisms that can lock pain into a chronic state. In that setting, a compound with both analgesic and anti-inflammatory properties draws attention quickly, especially when it appears to act upstream of central sensitization rather than only masking symptoms.
In this preclinical study, Shikonin was tested in rats with bone cancer pain induced by intratibial inoculation of luciferase-labeled MADB106 cells. The investigators administered the agent intrathecally and followed not only mechanical and thermal pain responses, but also gait, anxiety-like behavior, and motor coordination. The design matters because bone cancer pain is rarely confined to one sensory domain; it alters movement, confidence, and function in parallel with nociceptive thresholds.
The analgesic effect emerged in a dose- and time-dependent manner. Shikonin produced an estimated ED50 of 29.80 μg/kg and did not cause an apparent impairment in rotarod performance, which argues against a simple sedative or grossly motor-impairing explanation for the pain response. In practical terms, the compound lowered pain behavior without erasing the animals’ ability to coordinate movement on a balance task.
Functional recovery extended beyond nociceptive thresholds
Pain in this model was not treated as a laboratory abstraction. CatWalk gait analysis showed improvement in the abnormalities that typically accompany skeletal pain, and the behavioral battery extended into open field, elevated plus maze, and light/dark box testing. Those measures are relevant because chronic pain often reshapes behavior through fear of movement and stress-related avoidance, not just through raw stimulus sensitivity.
A single result stands out sharply: Shikonin improved both sensory and affective dimensions of the syndrome. The reduction in pain related anxiety-like behaviors suggests that the intervention may have interrupted a broader spinal pain program rather than only dulling reflexive responses. In a disease state driven by continuous peripheral insult from tumor-bearing bone, that breadth is biologically plausible.
The study also used bioluminescence imaging and hematoxylin-eosin staining to confirm tumor development and characterize bone pathology. Those methods anchored the analgesic findings to the underlying cancer model, helping separate drug effect from a failure of tumor establishment.
IGF2 and p38 MAPK emerged as the spinal signaling axis
Transcriptomic sequencing of the spinal dorsal horn identified Igf2 as a candidate gene responsive to Shikonin treatment. That finding led the investigators into a focused signaling analysis, where spinal IGF2 expression and p38 phosphorylation were increased during bone cancer pain development. The pairing is important: IGF2 can act as a growth-related and signaling molecule, while p38 MAPK is a classic mediator of inflammatory and nociceptive amplification in the central nervous system.
Shikonin reduced both IGF2 expression and p38 phosphorylation in the spinal dorsal horn. At the same time, spinal levels of IL-6, IL-1β, and TNF-α declined. This cluster of changes fits a model in which the drug reduces neuroinflammatory drive within the spinal cord, lowering the gain on pain transmission and limiting the persistence of hypersensitivity. In bone cancer pain, where peripheral tumor signals continuously bombard the nervous system, that kind of central dampening can have outsized behavioral consequences.
The molecular work did not stop at correlation. Intrathecal IGF2 siRNA reproduced the analgesic and behavioral effects of Shikonin and also reduced p38 phosphorylation. By contrast, the p38 inhibitor Adezmapimod (SB203580) reproduced key behavioral effects without a marked change in IGF2 expression. Combined treatment with Shikonin and either IGF2 knockdown or p38 inhibition did not yield significant additional behavioral benefit. In a mechanistic sense, those nonadditive findings support a shared pathway rather than two independent analgesic routes running in parallel.
What the pathway architecture suggests about spinal pain amplification
The sequence of effects points to IGF2 acting upstream of p38 MAPK in the spinal dorsal horn during bone cancer pain. If IGF2 signaling helps drive p38 activation, then suppressing IGF2 would be expected to reduce downstream inflammatory and nociceptive transcriptional activity. The cytokine reductions observed here are consistent with that arrangement. Once p38 activity is already suppressed, pushing the system further with Shikonin may offer little extra behavioral gain, which is exactly what the combination experiments suggested.
This is a useful mechanistic frame because p38 MAPK has long been implicated in pain sensitization and glial-neuronal signaling. A drug that attenuates that pathway without producing obvious motor toxicity in this model carries conceptual appeal for chronic pain states that are both severe and function-limiting. Still, the evidence remains preclinical, and intrathecal delivery narrows the translational context. Human use would require a very different safety and delivery calculus.
One sentence captures the study’s central signal: Shikonin did more than suppress nociception; it interrupted a spinal inflammatory signaling program linked to tumor-driven pain.
Preclinical promise, but the translational gap remains wide
The findings position Shikonin as a candidate for further study in cancer-associated pain, especially where spinal neuroinflammation and central sensitization dominate the phenotype. The work also strengthens the case for IGF2-associated signaling as a relevant therapeutic node in bone cancer pain. Even so, this is still a rat study with intrathecal dosing, and the results cannot be assumed to predict clinical efficacy, tolerability, or feasible delivery in patients.
The most important unanswered issues are straightforward and concrete: whether the same mechanism operates in other bone cancer pain models, whether systemic administration can reproduce the effect, and how durable the analgesia would be with repeated dosing. Peer review may also clarify how broadly the pathway extends beyond this single tumor model. For now, the data support a mechanistic story in which Shikonin suppresses spinal IGF2-associated p38 MAPK signaling and, in doing so, reduces the sensory and behavioral burden of bone cancer pain in rats.